A 4% lidocaine topical cream (distributed under the Kirkman / Dermal label) has been recalled. Numbing cream is so routine in a medspa — before injectables, microneedling, laser, tattoo work — that it's easy to forget it's a drug with real risks.
The practical step is simple: check your treatment-room drawers and any retail shelf for this product and lot, and set anything matching aside until you've confirmed against the official notice.
The reminder underneath it is worth repeating to staff. High-percentage lidocaine, spread over large areas or under occlusion, can be absorbed enough to cause systemic toxicity — there are documented deaths tied to aggressive pre-treatment numbing. Recall or not, this is a good prompt to review how much your team applies, where, and for how long.
The affected lots and the reason for the recall are in the FDA record.
View the official FDA record ↗
This post summarizes a public FDA database entry for medical-aesthetics owners. It is general business information, not medical, legal, or regulatory advice. Always confirm scope, lot numbers, and classification against the official FDA record, and consult your own clinician or counsel for anything clinical or compliance-related.